Although prostate cancer screening has been traditionally tackled by monitoring prostate-specific antigen (PSA), a protein whose circulating levels increase in the serum of prostate cancer patients, its selectivity is reduced, leading to a high number of false positive results and, in turn, unnecessary biopsies and overtreatment [16,17]. The gene discussed is KLK3; the disease is prostate cancer.